Funding for TransTech

- Last updated on GMT

Related tags: Pharmacology

US TransTech Pharma has completed two rounds of investments in the
company, extending over the last nine months, totalling $24.5
million (€22.8m). The investments came from its largest
shareholder, New York-based MacAndrews & Forbes Holdings, as
well as its research partners Novo Nordisk and Cephalon Investors.

US TransTech Pharma has completed two rounds of investments in the company, extending over the last nine months, totalling $24.5 million (€22.8m). The investments came from its largest shareholder, New York-based MacAndrews & Forbes Holdings, as well as its research partners Novo Nordisk and Cephalon Investors.

Adnan Mjalli, president and chief executive officer of TransTech, said: "We believe that these substantial equity investments in our company demonstrate confidence in our innovative technologies, our ability to accelerate the drug development process and our various drug discovery programs.

After just three years of operation, we are advancing two small- molecule programs towards clinical trials and three others into pre-clinical testing, and have helped our research partners achieve substantial progress against multiple therapeutic targets."

TransTech will use a portion of the proceeds to advance two internal programs into Phase I clinical trials during 2003. The two programs are focused on advancing novel, orally bio-available small-molecule antagonists that are directed at novel protein-protein interactions in several therapeutic areas.

In addition to carrying out its internal drug discovery programs, TransTech has also been active with three multi-year research collaborations - with Novo Nordisk, Cephalon and SIGA Technologies - each with focus directed at the discovery of small molecule drug candidates in various therapeutic areas.

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more